Fundz

VETmAb Biosciences secures funding from TL Foundation to accelerate growth in developing monoclonal antibody therapies for pets. This investment aims to enhance San Diego's economic future and support local veterinary biotechnology.

PRIVATENov 17, 2026

Round Type

Venture

San DiegoBiotechnologyHealth Care

Investors

TL Foundation

Description

TL Foundation has invested in VETmAb Biosciences, a company led by experienced San Diego veterinary biotechnology founders. This funding will accelerate research and development of new treatments for chronic diseases affecting pets. The investment aims to strengthen the local economy by creating jobs and attracting additional capital. The team formerly built Kindred Biosciences, which achieved significant veterinary FDA product approvals.

Quick answer

VETmAb Biosciences raised an undisclosed amount in a funding round, dated November 17, 2026. Investors: TL Foundation. VETmAb Biosciences is based in San Diego, California, United States.

How much did VETmAb Biosciences raise?
VETmAb Biosciences raised an undisclosed amount in a funding round on November 17, 2026.
Who invested in VETmAb Biosciences?
TL Foundation is named as investors in this round.
What does VETmAb Biosciences do?
VETmAb Biosciences (VETmAb BIO) is a veterinary biotechnology company focused on developing monoclonal antibody therapies for chronic diseases affecting pets.
Where is VETmAb Biosciences based and how big is it?
VETmAb Biosciences is based in San Diego, California, United States.

Source: Fundz verified event record.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as VETmAb Biosciences that raised within 45 days of this round, from Fundz verified event records.

  • AstraNu raised $3.5M (Seed) on November 17, 2026.
  • Soombit AI raised $9M (Series A) on November 17, 2026.
  • TestDynamics raised $9M (Series A) on November 16, 2026.
  • 201 Therapeutics raised $178K (Seed) on November 16, 2026.
  • Seawolf Therapeutics raised $100M (Seed) on November 16, 2026.
  • Raywatt raised $9.9M (Series B) on November 16, 2026.

Who to call at VETmAb Biosciences, and when

A new round usually means VETmAb Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day VETmAb Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at VETmAb Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at VETmAb Biosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

VETmAb Biosciences

Location

San Diego, California, United States

About

VETmAb Biosciences (VETmAb BIO) is a veterinary biotechnology company focused on developing monoclonal antibody therapies for chronic diseases affecting pets. Founded by experienced local entrepreneurs, the company aims to transform veterinary care with innovative treatments. With a successful track record from their previous company, they are committed to contributing to the economic growth of San Diego while providing life-changing solutions for pets and their families.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment VETmAb Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for VETmAb Biosciences's next move

See what Strategic adds

VETmAb Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.